Creative Biolabs’ Abundant Antibody Products for Ebolavirus Research Are Readily Available

 Breaking News
  • No posts were found

Creative Biolabs’ Abundant Antibody Products for Ebolavirus Research Are Readily Available

August 01
13:38 2019
Creative Biolabs provides various Ebolavirus antibody products of high standards worldwide to support clinical research relevantly aiming to solve problems encountered by customers working in the medical research or relevant area.

New York, US—August 1, 2019 In the Democratic Republic of the Congo, the out-breaking Ebola virus in North Kivu and Ituri provinces continues raging and there are still many cases emerging every day, according to the World Health Organization’s updated report on the Ebola epidemic. Targeting at this headache bothering the WHO and people in South Africa, Creative Biolabs provides various types of recombinant Ebolavirus antibody products to facilitate the Microbiology research, which can bring hopes to the drug and vaccine manufacturing.


Brief Introduction

Ebola virus (EBOV), as rare as it is, originally appeared in 2 simultaneous outbreaks in 1976, one in Nzala, South Sudan, and the other occurred in a village near the Ebola River, and hence got the name. Infection with Ebola virus disease (EVD) usually has a latent period of 4 to 10 days with initial symptoms similar to influenza, manifesting as vomiting and diarrhea, followed by internal and external bleeding, accompanied by sudden shock, and finally multiple organ failure. Patients usually die 6 to 16 days after symptoms occur.



Due to the fact that discriminating EVD from malaria, typhoid fever, meningitis and other infectious diseases is relatively difficult, scientists have developed a series of methods to be adopted, to which the multifarious products from Creative Biolabs can be applicable, including Enzyme-linked Immunosorbent Assay (ELISA), Immunocytochemistry, Immunofluorescence, etc. The provided abundant recombinant Sudan ebolavirus antibodies target at the L (an RNA-dependent RNA polymerase and a component of viral polymerase complex) and GP (toxic protein) of EBOV, of which the peptide sequences correspond to the important amio acid residues like TRSFTTHFL, MSDIFHALV, GFKLRSAVM, and TTLPSQNST, etc.



Up to now, there is no approval treatment for Ebola virus disease. Existing EBOV vaccines include DNA vaccine, recombinant subunit vaccine, virus-like particle vaccine and virus vector vaccine. Creative Biolabs is concentrating on facilitating the medical researchers or drug industry to develop various possible treatments, like blood products, immunotherapy and drug therapy that are currently being evaluated.


“We hope to help the research and development of EBOV drugs or therapies,” said the Head of Creative Biolabs. The serious disease has attacked Africa many times, and all the medical workers are working on the whole-hearted study of effective treatment. As a piloting distributor in the area of recombinant Ebolavirus antibody, Creative Biolabs is certainly contributing under the support of experienced scientists. More details about the Ebola virus antibodies are available at


About Creative Biolabs

Since 2004, Creative Biolabs started working on offering high-quality services in academic and life science worldwide. As the leading role in discovering and manufacturing recombinant antibodies, advanced antibody research tools, professional technical support, and rapid global delivery are utilized to ensure quality for scientific research workers and customers in industry. A custom-service-centered business model is taken seriously for optimizing the drug development process, leveraging accessible resources, and gathering a team from various backgrounds to conduct drug discovery projects in the future.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States

September 2019
« Aug